Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Register Stunning Growth During the Forecast Period (2022-32) | Pfizer (TALZENNA), Clovis Oncology (Rubraca), AstraZeneca (LYNPARZA)

 Breaking News
  • No posts were found

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Register Stunning Growth During the Forecast Period (2022-32) | Pfizer (TALZENNA), Clovis Oncology (Rubraca), AstraZeneca (LYNPARZA)

October 06
19:08 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Register Stunning Growth During the Forecast Period (2022-32) | Pfizer (TALZENNA), Clovis Oncology (Rubraca), AstraZeneca (LYNPARZA)
Delveinsight Business Research LLP
As per DelveInsight, the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities in the domain, rise in the number of companies taking an interest in developing specific drugs for mCRPC along with increasing awareness and penetration of already approved prostate cancer drugs in mCRPC

Globally, several key pharma and biotech companies are working in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Castration-Resistant Prostate Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Metastatic Castration-Resistant Prostate Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Overview

Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones and is known as distant or metastatic prostate cancer.

Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Key Facts

  • Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.

  • The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,385 cases in 2017, which is expected to grow during the study period. In total prevalent cases of the 7MM, the US accounted for the highest number of cases which were 3,170,339 cases in 2017.

  • Among the EU-5 countries, Germany had the highest diagnosed prevalent population of Prostate Cancer, followed by France and Italy. On the other hand, Spain had the lowest diagnosed prevalent population in 2017.

  • Furthermore, Japan accounted for about 9% of the total 7MM diagnosed prevalent population with prostate cancer (in 2017).

  • According to the analysis, it was found that prostate cancer is more prevalent in people of age between 65–74 years, followed by 55–64 years and 75–84 years.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market

The mCRPC Market dynamics are anticipated to change in the coming years owing to the rise in the number of companies taking an interest in developing specific drugs for mCRPC along with increasing awareness and penetration of already approved prostate cancer drugs in mCRPC.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Castration-Resistant Prostate Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Metastatic Castration-Resistant Prostate Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology Segmentation

  • Total Prevalent Cases of Prostate Cancer

  • Total Treated Cases of Metastatic CRPC

  • Age-specific Cases of Prostate Cancer

  • Total Diagnosed Cases of Prostate Cancer by Clinical Stages

  • Total Diagnosed Cases of Prostate Cancer

  • Total Metastatic Cases of CRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Castration-Resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Castration-Resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Outlook

As per DelveInsight’s assessment, the treatment paradigm of Metastatic Castration-Resistant Prostate Cancer is full of competition as many of the approved therapies are already present in the market, and many of the therapies are present in the pipeline, expected to fulfill the unmet needs in mCRPC treatment in the coming years.

• On October 04, 2022, Pfizer revealed positive topline results from the Phase 3 TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC). 

• In August 2022, AstraZeneca and Merck (NYSE: MRK) announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone had been accepted and granted priority review by the US FDA for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in an adult patient. As per the updates, the FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date in the fourth quarter of 2022.

Learn How Metastatic Castration-Resistant Prostate Cancer Market Will Evolve by 2032 @ 

https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market

Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Emerging Therapies and Key Companies 

Several major pharma and biotech giants are developing therapies for Metastatic Castration-Resistant Prostate cancer. Currently, Clovis Oncology has its Metastatic Castration-Resistant Prostate cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Metastatic Castration-Resistant Prostate Cancer Market include

Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and several others.

Metastatic Castration-Resistant Prostate Cancer Drugs Covered in the report include:

SRF617: Surface Oncology

Rucaparib: Clovis Oncology

HP518: Hinova Pharmaceuticals

Niraparib (Zejula): Janssen Research & Development

Talzenna (talazoparib): Pfizer/Astellas Pharma

Capivasertib: AstraZeneca

Ipatasertib (RG7440): Hoffmann-La Roche

LAE001: Laekna Therapeutics

Opdivo (nivolumab) and Keytruda (Pembrolizumab/MK-3475): Bristol-Myers Squibb /Merck

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More – 

https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Metastatic Castration-Resistant Prostate Cancer Competitive Intelligence Analysis

4. Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance

5. Metastatic Castration-Resistant Prostate Cancer Disease Background and Overview

6. Metastatic Castration-Resistant Prostate Cancer Patient Journey

7. Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population (In US, EU5, and Japan)

8. Metastatic Castration-Resistant Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Metastatic Castration-Resistant Prostate Cancer Unmet Needs

10. Key Endpoints of Metastatic Castration-Resistant Prostate Cancer Treatment

11. Metastatic Castration-Resistant Prostate Cancer Marketed Products

12. Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Latest Therapeutic Advances

13. Metastatic Castration-Resistant Prostate Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Metastatic Castration-Resistant Prostate Cancer Market Outlook (In US, EU5, and Japan)

16. Metastatic Castration-Resistant Prostate Cancer Access and Reimbursement Overview

17. KOL Views on the Metastatic Castration-Resistant Prostate Cancer Market

18. Metastatic Castration-Resistant Prostate Cancer Market Drivers

19. Metastatic Castration-Resistant Prostate Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Pancreatic Ductal Carcinoma Market

“Pancreatic Ductal Carcinoma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Pancreatic Ductal Carcinoma Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories